Xencor Q1 net loss narrows to $48.4M; CDO Valente resigns, Phase 2b UC study on track

Xencor Inc

2025-Q1 EPS reported -$0.66 revenue$32,732,000

Q1 revenue $32.7M (up from $16.0M YoY); net loss $48.4M (-$0.66 EPS) versus $73.4M (-$1.20 EPS) prior year.
Cash $693.5M at March 31; expects year-end 2025 cash $535-585M, funding operations into 2028.
Nancy Valente, EVP & CDO, to resign June 6, 2025, remain as senior advisor; clinical leaders report to CEO.
XmAb942 interim Phase 1 shows half-life >71 days, supports Q12W maintenance dosing; Phase 2b XENITH-UC starts H2 2025.
Earned $12.5M milestone from Incyte for tafasitamab sBLA acceptance, $2.0M from Vir for tobevibart Phase 3 start.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nancy Valente

Executive Vice President and Chief Development Officer

XNCR · Xencor Inc

Effective: 2025-06-06
Filed: May 7, 2025, 7:59 PM ET

On May 5, 2025, Nancy Valente, Executive Vice President and Chief Development Officer, notified the Company of her intention to resign from the Company effective June 6, 2025, and remain as a senior advisor.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nancy Valente resigned as Executive Vice President and Chief Development Officer at Xencor Inc.

Action: resigned
Role: Executive Vice President and Chief Development Officer

Exact text from the filing

On May 5, 2025, Nancy Valente, Executive Vice President and Chief Development Officer, notified the Company of her intention to resign from the Company effective June 6, 2025, and remain as a senior advisor.

View on SEC.gov

Xencor Inc filing history →

Source: SEC EDGAR

accession 0001326732-25-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.